Optimising Accuracy and Cost-Effectiveness of Screening for Pulmonary Arterial Hypertension in Scleroderma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1071735

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Scleroderma is one of the most devastating diseases of the immune system. With features that affect every organ in the body, scleroderma shortens the average patient’s life by over three decades. Pulmonary arterial hypertension (PAH), a condition of increased resistance in the blood vessels of the lungs, is the major cause of death in this disease. The purpose of this project is to develop a new 'screening' model for the early detection of PAH in scleroderma, thereby enabling earlier initiation of life-saving treatment.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Early Career Fellowships

Funding Amount: $375,403.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Rheumatology and Arthritis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | echocardiography | pulmonary hypertension | scleroderma | screening

Related Links